Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela

- October 29th, 2018

Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced positive top-line results from its Phase III trial of Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP). As quoted in the press release: Baxdela was compared to moxifloxacin in this randomized global … Continued

Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced positive top-line results from its Phase III trial of Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP).

As quoted in the press release:

Baxdela was compared to moxifloxacin in this randomized global trial. Baxdela met all key primary and secondary endpoints in the trial, including the study’s primary U.S. Food and Drug Administration (FDA) endpoint showing Early Clinical Response (ECR) with improvement at 96 hours (± 24 hours) after the first dose in at least two of the following symptoms: chest pain, frequency or severity of cough, amount of productive sputum, and difficulty breathing.

In the intent-to-treat population (ITT), IV-to-oral Baxdela met the FDA primary endpoint of statistical non-inferiority (12.5% non-inferiority margin) for the Early Clinical Response at 96 hours (± 24 hours) after initiation of therapy (88.9% ECR in Baxdela patients) compared to IV/oral moxifloxacin (89.0%). The 95% confidence interval for the treatment difference had lower and upper bounds of -4.4% and 4.1%, respectively.

Baxdela also met the FDA secondary endpoint of statistical non-inferiority (90.5%) compared to moxifloxacin (89.7%) based on the investigator’s assessment of Success at the Test of Cure visit (5-10 days after last dose) in the ITT population. Lower and upper bounds of the 95% confidence interval for the treatment difference were -3.3% and 4.8%, respectively.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis


Read our new report today

Leave a Reply

Your email address will not be published. Required fields are marked *